Highly Selective CDK7 Inhibitor Q901 in Advanced Solid Tumors
Phase 1/2
130
about 4 years
18+
7 sites in AZ, CA, FL +4
About this study
This trial is testing a new drug called Q901, which blocks the activity of CDK7. It's being tested in people with advanced solid tumors who have not responded to other treatments. The goal is to see if Q901 can help shrink or control the cancer and how safe it is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take KEYTRUDA® (pembrolizumab)
- 2.Take Q901
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary: Change in the area under curve (AUC) of Q901, Change in the maximum plasma concentration (Cmax) of Q901, Change in the time of maximum plasma concentration (Tmax) of Q901